Skip to main content
Smart Investors Daily
SH

NASDAQ · SHPH

Shuttle Pharmaceuticals Holdings, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

$4.58

Up+$0.35 (+8.27%)

Updated Aug 14, 2026, 9:25 AM

SID Score

5.8/10

Composite research score

Smart Money

Institutional and insider signal

Market cap
1.88M
P/E ratio
-0.37
Dividend yield
0.00%
52-week range
$0.49 – $6.15
Volume
94.7K
Avg. volume
320.11K

Price performance

SHPH price history

1M range · 21 trading sessions · Daily adjusted prices

SHPH closed at $4.58 after 21 trading sessions, up 29.01% for the selected period.

Last close
$4.58
Period change
+29.01%
Period low
$2.78
Period high
$4.60
Daily close
View OHLC price history
SHPH OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 13, 2026$4.19$4.80$4.19$4.5894.7K
Aug 12, 2026$4.33$4.33$4.12$4.2316.02K
Aug 11, 2026$4.06$4.32$3.9428$4.3120.55K
Aug 10, 2026$4.21$4.21$3.8901$4.0736.04K
Aug 7, 2026$4.51$4.5399$4.32$4.3657.41K
Aug 6, 2026$4.29$4.51$4.06$4.3882.61K
Aug 5, 2026$4.03$4.60$3.84$4.601.59M
Aug 4, 2026$3.37$3.65$3.2609$3.65117.96K
Aug 3, 2026$3.36$3.5999$3.15$3.37184.57K
Jul 31, 2026$3.03$4.40$2.92$3.803.07M
Jul 30, 2026$2.86$3.15$2.8001$3.09201.13K
Jul 29, 2026$2.79$2.79$2.5764$2.78207.38K
Jul 28, 2026$2.86$2.90$2.71$2.7972.87K
Jul 27, 2026$2.86$2.93$2.78$2.92125.16K
Jul 24, 2026$2.93$2.93$2.78$2.8989.73K
Jul 23, 2026$3.00$3.04$2.90$2.99113.66K
Jul 22, 2026$3.04$3.2499$3.01$3.06130.95K
Jul 21, 2026$3.13$3.40$3.09$3.351.59M
Jul 20, 2026$3.18$3.21$2.96$3.033.1M
Jul 17, 2026$3.40$3.40$3.02$3.16132.95K
Jul 16, 2026$3.56$3.70$3.3501$3.55163.9K

Latest SHPH news

The latest Smart Investors Daily articles mentioning SHPH.

SHPH research

Overview

Company profile and research snapshot.

Company profile

Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. It is developing a pipeline of products designed to address the limitations of the current cancer therapies as well as to extend to the new applications of RT. The company believes that its product candidates will enable the company to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Average target
Implied upside
Analysts
Open full forecast

News briefing

No generated briefing is available yet.

ChartMill · Jul 20, 2026

Top movers in Monday's after hours session

After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.